StockData
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc. (ANIK) stock

ANIKNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/30
$13.62+0.77 (+5.99%)

Close on Nov 18, 2026Market cap $182.28MP/E –Yield –

Anika Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Anika Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $5.98M, down 4.8% year over year. For fiscal 2025 it was $11.19M, up 107.1% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $40.81M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.19M+107.1%
FY2024Dec 31, 2024$5.40M–
FY2023Dec 31, 2023-$1.79M-140.6%
FY2022Dec 31, 2022$4.41M-47.5%
FY2021Dec 31, 2021$8.40M-35.7%
FY2020Dec 31, 2020$13.07M-64.7%
FY2019Dec 31, 2019$37.01M+6.0%
FY2018Dec 31, 2018$34.92M-14.4%
FY2017Dec 31, 2017$40.81M+66.9%
FY2016Dec 31, 2016$24.45M-38.7%
FY2015Dec 31, 2015$39.91M-0.2%
FY2014Dec 31, 2014$39.98M+58.9%
FY2013Dec 31, 2013$25.17M+138.6%
FY2012Dec 31, 2012$10.55M+3.7%
FY2011Dec 31, 2011$10.17M+29.5%
FY2010Dec 31, 2010$7.85M+153.8%
FY2009Dec 31, 2009$3.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$684.00K–
Q1 FY2026Mar 31, 2026-$4.85M–
Q4 FY2025Dec 31, 2025$4.64M+193.1%
Q3 FY2025Sep 30, 2025$6.87M+37.0%
Q2 FY2025Jun 30, 2025-$189.00K–
Q1 FY2025Mar 31, 2025-$130.00K–
Q4 FY2024Dec 31, 2024$1.58M-56.5%
Q3 FY2024Sep 30, 2024$5.02M-22.7%
Q2 FY2024Jun 30, 2024-$1.07M–
Q1 FY2024Mar 31, 2024-$126.00K–
Q4 FY2023Dec 31, 2023$3.64M+656.3%
Q3 FY2023Sep 30, 2023$6.49M+139.4%
Q2 FY2023Jun 30, 2023-$8.29M-368.6%
Q1 FY2023Mar 31, 2023-$3.62M–
Q4 FY2022Dec 31, 2022$481.00K-89.2%
Q3 FY2022Sep 30, 2022$2.71M+31.4%
Q2 FY2022Jun 30, 2022$3.09M-28.1%
Q1 FY2022Mar 31, 2022-$1.87M–
Q4 FY2021Dec 31, 2021$4.47M+72.9%
Q3 FY2021Sep 30, 2021$2.06M-64.8%
Q2 FY2021Jun 30, 2021$4.29M+20.3%
Q1 FY2021Mar 31, 2021-$2.43M-332.6%
Q4 FY2020Dec 31, 2020$2.59M-80.1%
Q3 FY2020Sep 30, 2020$5.87M-41.6%
Q2 FY2020Jun 30, 2020$3.57M-34.8%
Q1 FY2020Mar 31, 2020$1.05M-87.7%
Q4 FY2019Dec 31, 2019$13.02M+30.1%
Q3 FY2019Sep 30, 2019$10.05M-7.3%
Q2 FY2019Jun 30, 2019$5.47M+22.3%
Q1 FY2019Mar 31, 2019$8.46M-11.8%
Q4 FY2018Dec 31, 2018$10.01M+43.4%
Q3 FY2018Sep 30, 2018$10.84M-10.4%
Q2 FY2018Jun 30, 2018$4.47M-28.7%
Q1 FY2018Mar 31, 2018$9.59M-38.0%
Q4 FY2017Dec 31, 2017$6.98M+15.0%
Q3 FY2017Sep 30, 2017$12.10M+6.9%
Q2 FY2017Jun 30, 2017$6.27M–
Q1 FY2017Mar 31, 2017$15.46M–
Q4 FY2016Dec 31, 2016$6.07M–
Q3 FY2016Sep 30, 2016$11.32M–

More Anika Therapeutics figures

See a number that looks wrong?